1. Home
  2. WU vs NBTX Comparison

WU vs NBTX Comparison

Compare WU & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Union Company (The)

WU

Western Union Company (The)

N/A

Current Price

$6.10

Market Cap

1.9B

ML Signal

N/A

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

N/A

Current Price

$31.21

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WU
NBTX
Founded
1851
2003
Country
United States
France
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
WU
NBTX
Price
$6.10
$31.21
Analyst Decision
Sell
Strong Buy
Analyst Count
18
5
Target Price
$6.64
★ $54.14
AVG Volume (30 Days)
★ 7.0M
124.5K
Earning Date
11-04-2026
09-24-2026
Dividend Yield
★ 15.14%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.45
N/A
Revenue
★ $4,050,700,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.83
$50.69
P/E Ratio
$13.74
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$5.87
$17.43
52 Week High
$10.35
$57.14

Technical Indicators

Market Signals
Indicator
WU
NBTX
Relative Strength Index (RSI) 44.52 54.98
Support Level $5.91 $30.15
Resistance Level $6.40 $35.38
Average True Range (ATR) 0.17 1.76
MACD 0.02 1.50
Stochastic Oscillator 34.55 74.72

Price Performance

Historical Comparison
WU
NBTX

About WU Western Union Company (The)

Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2025 and is the largest money transfer company in the world.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: